These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35212384)

  • 1. Hypertensive Emergency After Initiating Ozanimod: A Case Report.
    Choi DK; Rubin DT; Puangampai A; Cleveland N
    Inflamm Bowel Dis; 2022 Aug; 28(8):e114-e115. PubMed ID: 35212384
    [No Abstract]   [Full Text] [Related]  

  • 2. Ozanimod in Crohn's disease: a promising new player.
    Sleutjes JAM; de Vries AC; van der Woude CJ
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):791-792. PubMed ID: 32553150
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: Ozanimod and latent tuberculosis.
    Alaskar D; AlMusa Z; AlAmeel T
    Aliment Pharmacol Ther; 2023 Feb; 57(3):353-354. PubMed ID: 36641788
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: ozanimod and latent tuberculosis-authors' reply.
    Zhang E; Christensen B
    Aliment Pharmacol Ther; 2023 Feb; 57(3):355-356. PubMed ID: 36641790
    [No Abstract]   [Full Text] [Related]  

  • 5. Ozanimod: First Approval.
    Lamb YN
    Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ozanimod for Ulcerative Colitis.
    Senussi NH; Rakov N
    N Engl J Med; 2022 Jan; 386(2):194. PubMed ID: 35020994
    [No Abstract]   [Full Text] [Related]  

  • 7. Ozanimod for Ulcerative Colitis.
    Macaluso FS; Orlando A
    N Engl J Med; 2022 Jan; 386(2):194. PubMed ID: 35020993
    [No Abstract]   [Full Text] [Related]  

  • 8. Ozanimod for the Treatment of Ulcerative Colitis.
    Khanna R; Chande N; Marshall JK
    Gastroenterology; 2022 Jun; 162(7):2104-2106. PubMed ID: 35122762
    [No Abstract]   [Full Text] [Related]  

  • 9. Ozanimod for Ulcerative Colitis. Reply.
    Sandborn WJ; Danese S
    N Engl J Med; 2022 Jan; 386(2):194-195. PubMed ID: 35020995
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L; Paul F
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    Swallow E; Patterson-Lomba O; Yin L; Mehta R; Pelletier C; Kao D; Sheffield JK; Stonehouse T; Signorovitch J
    J Comp Eff Res; 2020 Mar; 9(4):275-285. PubMed ID: 31948278
    [No Abstract]   [Full Text] [Related]  

  • 13. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW; Cohen JA; Comi G; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Havrdova EK; Cree BAC; Minton N; Sheffield JK; Ding N; Kappos L
    Mult Scler Relat Disord; 2021 Jun; 51():102844. PubMed ID: 33892317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positioning Ozanimod in Ulcerative Colitis: Restoring Leukocyte Traffic Under Control.
    D'Amico F; Allocca M; Fiorino G
    Gastroenterology; 2022 May; 162(6):1767-1769. PubMed ID: 34896116
    [No Abstract]   [Full Text] [Related]  

  • 15. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
    Surapaneni S; Yerramilli U; Bai A; Dalvie D; Brooks J; Wang X; Selkirk JV; Yan YG; Zhang P; Hargreaves R; Kumar G; Palmisano M; Tran JQ
    Drug Metab Dispos; 2021 May; 49(5):405-419. PubMed ID: 33674268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.